Hi. As I have stated in my earlier post, untreated stage 4 endometrial cancer has a five year survival rate between less than 5% to 25%. I suppose that the more aggressive histologic subtypes of stage 4 endometrial cancer will tend to have a survival rate on the lower end of the range I have given. A study on the efficacy of Taxol/Carboplatinum regimen in advanced or recurrent endometrial cancer (see http://jco.ascopubs.org/cgi/content/full/19/20/4048) found a 63% 3-year survival rate when this regimen was used.
Hello,
Thanks for your reply.They say i have poorly differentiated adenocarcinoma of endometrium which has spread to my bowels(peritoneal carcinomatosis).its a very virulent tumor.They want to start chemo with taxol/carboplatinum every 3 weeks(6 cycles).What do you think?is it really worth going through the chemo?what is the survival of this type of cancer with chemo and without chemo.
Thanks again
Hi. Various sources estimate the five year survival rate for untreated stage 4 endometrial cancer from less than 5% to 25%. The study evaluating the combination chemotherapy doxorubicin plus cisplatin for advanced stage endometrial cancer (see http://jco.ascopubs.org/cgi/content/full/24/1/36) yielded a five year survival of 50% for those treated with this drug combination. However, the women treated in that study was a mixed group who had stage 3 and stage 4 disease. The addition of the chemotherapy drug paclitaxel to the doxorubicin-cisplatin combination in advanced endometrial cancer results in even better median survival (see http://jco.ascopubs.org/cgi/content/full/22/11/2159#F2).